Pharma channel feed

NIH di­rec­tor nom­i­nee Bertag­nol­li skirts drug pric­ing ques­tions at con­fir­ma­tion hear­ing

Last year
People
FDA+

Big Phar­mas part­ner with HBCU, with aim to cre­ate the largest African an­ces­try ge­nomics data­base

Last year
R&D

Ora­sis gains FDA ap­proval for pres­by­opia eye drops, fol­low­ing in Ab­b­Vie’s foot­steps

Last year
FDA+

UCB wins FDA ap­provals in plaque pso­ri­a­sis and gMG, un­lock­ing block­buster op­por­tu­ni­ties

Last year

FDA ap­proves new in­di­ca­tion for Arde­lyx's tena­panor for serum phos­pho­rus con­trol

Last year
FDA+

Scoop: Eli Lil­ly agrees to ac­quire an­oth­er Eu­ro­pean ADC biotech

Last year
Startups
Deals

Up­dat­ed: ES­MO em­bar­go break leads can­cer con­fer­ence to re­lease da­ta for Bris­tol My­ers, J&J, No­var­tis, As­traZeneca

Last year
R&D

US vs. Eu­rope: New re­search pa­per com­pares drug re­view times across bor­ders

Last year
FDA+

J&J lays out plans for po­ten­tial Supreme Court pe­ti­tion in talc lit­i­ga­tion

Last year
Law

Q&A: Lil­ly sci­ence chief Dan Skovron­sky talks deal­mak­ing, AI and con­sis­tent in­vest­ing

Last year
Deals

Af­ter con­sumer spin­off, John­son & John­son re­ports Q3 sales in­crease and bumps up full-year guid­ance

Last year

Spark lines up next reti­nal gene ther­a­py pact in Barcelona

Last year
Deals
Cell/Gene Tx

Bris­tol My­ers scores an­oth­er Op­di­vo ap­proval, as Mer­ck con­verts AA to full ap­proval for Keytru­da in MCC

Last year
FDA+

Ab­b­Vie’s Skyrizi helps more Crohn's pa­tients stay off steroids than J&J’s Ste­lara, PhI­II da­ta show

Last year
R&D

No­vo Nordisk to buy PhI­II kid­ney dis­ease drug from Sin­ga­pore's KBP Bio­sciences

Last year
Deals

Up­dat­ed: Pfiz­er plans $3.5B in cost cuts amid Covid slide, while Mod­er­na sticks by guid­ance

Last year

Pfiz­er's El­rex­fio, Astel­las' Veozah among new drugs rec­om­mend­ed for au­tho­riza­tion by Eu­ro­pean reg­u­la­to­ry com­mit­tee

Last year
FDA+

Ex­clu­sive: Hori­zon CEO Tim Wal­bert talks M&A, FTC post-Am­gen deal close

Last year
People

Re­lay Ther­a­peu­tics points to drug price ne­go­ti­a­tions for de­lay in po­ten­tial block­buster can­cer drug

Last year
Law

No­vo rais­es 2023 out­look due to high­er than ex­pect­ed Ozem­pic and We­govy sales in the US

Last year

Op­ti­miz­eRx builds out pa­tient DTC mar­ket­ing with $95M ac­qui­si­tion

Last year
Deals
Marketing

BIO, PhRMA, oth­ers seek tweaks to FDA draft guid­ance on di­ver­si­ty in post­mar­ket­ing stud­ies

Last year
FDA+

Am­gen gives first glimpse at PRMT5 in­hibitor, days af­ter Bris­tol My­ers put a $1B promise on the tar­get

Last year
R&D

Pfiz­er lands FDA ap­proval for $6.7B ul­cer­a­tive col­i­tis drug, tak­ing on an­ti­bod­ies as an oral al­ter­na­tive

Last year
R&D
FDA+
First page Previous page 96979899100101102 Next page Last page
A service from the Financial Times